Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?

被引：0
|
作者：
Tavara, B. [1 ]
Garrido, M. L. [1 ]
Rodriguez, Z. [1 ]
Rojas, M. [1 ]
Lopez, L. [1 ]
Medina, S. [1 ]
Ponte, C. [1 ]
Lopez, A. [1 ]
Sanchez, E. [1 ]
Pedraza, M. [1 ]
Vinals, P. [1 ]
Lopez, M. [1 ]
Alonso, D. [1 ]
Rodriguez, A. [1 ]
Davila, E. [1 ]
Castanon, C. [1 ]
De Sande, L. M. [1 ]
Nieto, B. [1 ]
Vallejo Pascual, M. E. [2 ]
Rodriguez, J. D. L. R. [1 ]
Garcia Palomo, A. [1 ]
Diz Tain, P. [1 ]
机构：
[1] Complejo Asistencial Univ Leon, Leon, Spain
[2] Univ Leon, Leon, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
DURVALUMAB; PACIFIC; REAL WORLD DATA;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP05.02-0
引用
收藏
页码：S283 / S283
页数：1
相关论文
共 50 条
  • [21] Durvalumab Adjuvant to Chemoradiation for Patients With Locally Advanced Non-Small Cell Lung Cancer: Real World Experience
    Haakensen, V. D.
    Nymoen, H. M.
    Langberg, C. W.
    Horndalsveen, H.
    Farooqi, S.
    Bjaanaes, M.
    Helland, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1045 - S1045
  • [22] Durvalumab improves prognosis of locally advanced non-small-cell Lung Cancer after definitive Radiochemotherapy
    Hecht, Markus
    Gaipl, Udo S.
    Fietkau, Rainer
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (03) : 269 - 271
  • [23] EFFICACY OF CONCURRENT CHEMORADIOTHERAPY IN LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER
    Almodovar, M.
    Ramos, H.
    Mota, P.
    Martins, V.
    Pereira, P.
    LUNG CANCER, 2011, 71 : S42 - S43
  • [24] Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer
    Huang, Yiqing
    Zhao, Joseph J.
    Soon, Yu Yang
    Wong, Alvin
    Aminkeng, Folefac
    Ang, Yvonne
    Asokumaran, Yugarajah
    Low, Jia Li
    Lee, Matilda
    Choo, Joan R. E.
    Chan, Gloria
    Kee, Adrian
    Tay, Sen Hee
    Goh, Boon Cher
    Soo, Ross A.
    THORACIC CANCER, 2022, 13 (22) : 3152 - 3161
  • [25] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer REPLY
    Antonia, Scott J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 990 - 990
  • [26] Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy
    Oh, H. -J.
    Park, C. -K.
    Kim, Y. -C.
    Kim, Y. -H.
    Ahn, S. -J.
    Jeong, W. G.
    Lee, J. Y.
    Lee, J. C.
    Choi, C. M.
    Ji, W.
    Song, S. Y.
    Choi, J.
    Lee, S. Y.
    Kim, H.
    Lee, S. Y.
    Park, J.
    Yoon, S. H.
    Joo, J. H.
    Oh, I. -J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S294 - S295
  • [27] Neoadjuvant chemotherapy and chemoradiotherapy for locally advanced non small cell lung cancer (NSCLC)
    Gavila, Q
    Almendros, P
    Camps, C
    López-Torrecillas, J
    Safont, M
    Blasco, A
    Garde, J
    Juarez, A
    Iranzo, V
    Sirera, R
    LUNG CANCER, 2005, 49 : S379 - S380
  • [28] Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy (CRT) in Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)
    Tanaka, K.
    Okamoto, I.
    Yamamoto, N.
    Hattori, Y.
    Masuda, N.
    Nishio, M.
    Takeda, K.
    Seto, T.
    Nishimura, Y.
    Nakagawa, K.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S605 - S605
  • [29] Real-world clinical efficacy of bevacizumab biosimilar in patients with advanced non-small-cell lung cancer
    Ou, Wei-Fan
    Hsu, Kuo-Hsuan
    Tseng, Jeng-Sen
    Lee, Po-Hsin
    Chen, Kun-Chieh
    Huang, Yen-Hsiang
    Chang, Gee-Chen
    Yang, Tsung-Ying
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [30] Treatment patterns and efficacy of durvalumab maintenance after CRT in real-world NSCLC patients
    Taugner, J.
    Kaesmann, L.
    Eze, C.
    Floersch, B.
    Guggenberger, J.
    Tufman, A.
    Reinmuth, N.
    Duell, T.
    Belka, C.
    Manapov, F.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S968 - S968
12345